Protalix BioTherapeutics, Inc.
PLX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -1.70 | 0.09 | 0.05 |
| FCF Yield | -2.40% | -4.87% | -2.73% | 2.58% |
| EV / EBITDA | 61.10 | 57.58 | -53.82 | 16.20 |
| Quality | ||||
| ROIC | 3.45% | 0.52% | -7.88% | 12.98% |
| Gross Margin | 53.37% | 62.51% | 19.11% | 78.67% |
| Cash Conversion Ratio | -1.58 | -31.91 | 1.40 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.94% | -2.80% | 13.25% | 3.88% |
| Free Cash Flow Growth | 25.32% | -5.59% | -250.42% | -11.25% |
| Safety | ||||
| Net Debt / EBITDA | -1.96 | -6.95 | 4.21 | -1.86 |
| Interest Coverage | 11.84 | 1.50 | -690.83 | 1,201.50 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.28 | 0.42 | 0.18 |
| Cash Conversion Cycle | 244.42 | 275.70 | 210.88 | 401.38 |